The incidence of M. tuberculosis resistance to linezolid and bedaquiline in patients for the period 2011-2022

The objective . To analyze the incidence of linezolid- and bedaquiline-resistant strains of M. tuberculosis from smear-positive TB patients in 2011–2022. Subjects and Methods . A total of 3637 clinical strains were obtained from patients undergoing treatment in the CTRI in 2011-2022. Drug susceptibility for linezolid and bedaquiline were determined using Bactec MGIT 960 (Becton Dickinson, USA) with a critical concentration of 1 mg/L. Results . 101 patients with linezolid- and bedaquiline-resistant strains were detected. The incidence of linezolid-resistance increases from 0,2% in 2011 to 5,5% in 2022 (p<0,05). The incidence of bedaquiline-resistance also increases from 1,4% in 2018 to 12,2% in 2022 (p<0,05). Conclusion . Resistance to linezolid and bedaquiline is increasing for the period 2011-2022. Molecular methods for linezolid and bedaquiline resistance detection are urgently needed.